Quantum Leap Healthcare Collaborative Concludes Famotidine Celebrex combination Does Not Reduce Time to Recovery or Mortality in Critically Ill Patients in the I-SPY COVID Trial
Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, today announced that the Famotidine Celecoxib arm has been dropped from the trial due to futility, based on the low likelihood of success. The Famotidine Celecoxib combination was chosen for testing because of their anti-histamine and anti-inflammatory mechanism of action.
Quantum Leap Healthcare Collaborative Concludes Cenicriviroc Not Likely to Reduce Time to Recovery or Mortality in Critically Ill Patients in I-SPY COVID Trial
Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, today announced that cenicriviroc (CVC) has been dropped from the trial due to futility, based on the low likelihood of success. CVC was chosen for testing because it is a CCR2/5 inhibitor, which has been hypothesized to potentially prevent fibrosis linked to the inflammation that accompanies critical illness associated with COVID-19.
I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Suggests Addition of Icatibant is Unlikely to Impact Critically Ill COVID-19 Patients
The I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC), was designed to rapidly screen agents that show promise for reducing the time to recovery (defined as reduction in oxygen demand) by approximately 50% or risk of mortality in critically ill COVID-19 patients. Today QLHC announced that, in addition to the razuprotafib and apremilast arms, the icatibant portion of the trial has concluded.
Quantum Leap Healthcare Collaborative Concludes Apremilast Not Likely to Reduce Time to Recovery or Mortality in Critically Ill Patients in I-SPY COVID Trial
Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, announced that apremilast (Otezla), made by Amgen, has been dropped for futility. Apremilast was chosen for testing in the I-SPY COVID Trial because it is a phosphodiesterase-4 (PDE4) inhibitor hypothesized to blunt the cytokine storm that accompanies critical illness associated with COVID-19.
Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical’s Razuprotafib in I-SPY COVID Trial
Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, will not proceed with further testing of the Aerpio Pharmaceuticals drug, razuprotafib. Razuprotafib was chosen for testing in the I-SPY COVID Trial because it is hypothesized to stabilize and repair the blood vessels in the lung and improve gas exchange.
HHS, DOD engage Quantum Leap Healthcare Collaborative in search for effective treatments for the sickest COVID-19 patients
In the race to identify safe and effective therapeutic treatments for the sickest COVID-19 patients, the U.S. Department of Health and Human Services and the Department of Defense are engaging a non-profit research organization, Quantum Leap Healthcare Collaborative of San Francisco, on a phase 2 clinical trial that rapidly screens multiple potential drugs simultaneously.
Susan G. Komen® Recognizes Renowned Investigators as 2020 Recipients of Brinker Awards for Scientific Distinction
Susan G. Komen®, the world’s leading breast cancer organization, recognized two widely respected and innovative breast cancer researchers this week, announcing that Donald McDonnell, Ph.D., and Laura Esserman, M.D., have been selected as this year’s recipients of the Brinker Awards – Komen’s highest scientific honor.
Laura Esserman, MD, Co-founder of Quantum Leap Healthcare Collaborative and Professor at UCSF, will speak at the TIME 100 Health Summit
Quantum Leap Healthcare Collaborative is pleased to announce that co-founder Dr. Laura Esserman will be among the speakers of the first-ever TIME 100 Health Summit, which will convene individuals from the TIME 100 community and prominent figures in healthcare to highlight essential perspectives on health and wellness, and to encourage cross-disciplinary collaboration toward a better, healthier world.
